Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Leukemia Breast Cancers Suppressed by Single Protein

By BiotechDaily International staff writers
Posted on 02 Feb 2012
Targeting a single protein can help combat both breast cancers and leukemia, according to two new reports. The single protein, HSP90, acts as a chaperone to protect other cellular proteins.

The study’s findings were published online January 23, 2012, in the Journal of Experimental Medicine. A team of investigators led by Ute Moll from the University of Gottingen (Germany) discovered that suppressing HSP90 activity rendered normally protected proteins susceptible to attack and destruction. One of these proteins--called migration inhibitory factor--fuels the growth of breast tumors. HSP90 inhibitors slowed the growth of migration inhibitory factor (MIF)-expressing breast tumors in mice but had little effect on tumors lacking MIF.

HSP90 inhibitors also look promising for certain forms of leukemia, according to a study by David Weinstock and coworkers at the Dana-Farber Cancer Institute (Boston, MA, USA). They demonstrated that HSP90 inhibitors slowed the growth of leukemia driven by hyperactive versions of the enzyme JAK2 (Janus kinase 2), many of which become resistant to JAK2-blocking drugs. The HSP90 inhibitors delayed the growth of resistant leukemia cells in mice.

According to the scientists, this research suggests that HSP90 may represent a therapeutic target for a range of cancers.

Related Links:

University of Göttingen
Dana-Farber Cancer Institute





Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.